Impact of the New National Cholesterol Education Program (NCEP) Guidelines on Patient Management
Authors:
- Anne Peters HarmelAHAnne Peters Harmel
- Kathy BerraKBKathy Berra
- 1 August 2003
- journal article
- review article
- Published by Wiley in Journal of the American Academy of Nurse Practitioners
- Vol. 15 (8) , 350-360
Abstract
Purpose To update nurse practitioners (NPs) on the latest National Cholesterol Education Program (NCEP) guidelines for the management of high blood cholesterol in adults. Data Sources The 2001 NCEP Adult Treatment Panel (ATP) III guidelines and supporting scientific reviews and reports of clinical trials related to the evidence upon which the guidelines are based. Conclusions The many new features of the ATP III guidelines include an increased emphasis on the patient with multiple risk factors in order to identify appropriate candidates for primary prevention and on more stringent classifications of elevated lipid/lipoprotein levels. However, elevated levels of low‐density lipoprotein (LDL) cholesterol continue to be the focus for both primary and secondary prevention, and 3‐hydroxy‐3‐methylglu‐tarylcoenzyme A (HMG‐CoA) reductase inhibitors (statins) are clearly the drugs of choice for decreasing LDL cholesterol in most patients. Implications for Practice Because NPs play key roles in optimizing treatment management, it is important that they become familiar with, and be prepared to help implement, these latest guidelines. By embracing the global risk assessment approach of ATP III and aggressively treating all at‐risk patients, NPs can take a proactive role in helping to halt the progression of coronary heart disease and its consequences.Keywords
This publication has 12 references indexed in Scilit:
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled TrialJAMA, 2001
- Effect of Statins on Risk of Coronary DiseaseJAMA, 1999
- Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery DiseaseNew England Journal of Medicine, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based careArchives of internal medicine (1960), 1995
- Reducing Low-Density Lipoprotein Cholesterol Levels in an Ambulatory Care SystemArchives of internal medicine (1960), 1995
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995